About NextCure, Inc.

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.

At the moment the company generates 4M USD in revenues.

On its last earning announcement, the company reported a loss of -1.30$ per share.

The book value per share is 7.50$

NextCure, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
4M - -33M -749.40% -30M -1.30 - - 23M 7.50 -3M -4M -8M